Allogene Therapeutics, Inc.
ALLO
$1.45
$0.053.57%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 21.29% | 17.64% | 23.44% | 18.93% | 3.86% |
| Total Depreciation and Amortization | -3.94% | 0.67% | 1.21% | 0.97% | -0.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -29.17% | -2.30% | -9.68% | -12.44% | -4.98% |
| Change in Net Operating Assets | -16.39% | -571.66% | -308.49% | -205.94% | -646.75% |
| Cash from Operations | 15.75% | 11.71% | 4.00% | -3.69% | -7.81% |
| Capital Expenditure | 54.22% | 79.58% | 93.79% | 88.69% | 70.80% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -53.65% | -40.16% | -37.38% | -70.31% | 48.01% |
| Cash from Investing | -53.65% | -39.34% | -36.49% | -69.98% | 53.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 19.54% | 13.83% | 21.70% | 3,234.98% | 3,143.90% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 21.92% | 16.22% | 24.17% | 3,234.98% | 3,143.90% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -137.35% | -252.32% | -72.91% | -331.70% | 119.07% |